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ABSTRACT
Targeting active angiogenesis, which is a major hall-
mark of malignant gliomas, is a potential therapeutic ap-
proach. For effective inhibition of tumor-induced neovascu-
larization, antiangiogenic compounds have to be delivered in
sufficient quantities over a sustained period of time. The
short biological half-life of many antiangiogenic inhibitors
and the impaired intratumoral blood flow create logistical
difficulties that make it necessary to optimize drug delivery
for the treatment of malignant gliomas. In this study, we
compared the effects of endostatin delivered by daily sys-
temic administration or local intracerebral microinfusion on
established intracranial U87 human glioblastoma xenografts
in nude mice. Noninvasive magnetic resonance imaging
methods were used to assess treatment effects and additional
histopathological analysis of tumor volume, microvessel
density, proliferation, and apoptosis rate were performed.
Three weeks of local intracerebral microinfusion of endosta-
tin (2 mg/kg/day) led to 74% (P < 0.05) reduction of tumor
volumes with decreased microvessel densities (33.5%, P <
0.005) and a 3-fold increased tumor cell apoptosis (P <
0.002). Systemic administration of a 10-fold higher amount
of endostatin (20 mg/kg/day) did not result in a reduction of
tumor volume nor in an increase of tumor cell apoptosis
despite a significant decrease of microvessel densities
(26.9%, P < 0.005). Magnetic resonance imaging was used
to successfully demonstrate treatment effects. The local mi-
croinfusion of human endostatin significantly increased sur-
vival when administered at 2 mg/kg/day and was prolonged
further when the dose was increased to 12 mg/kg/day. Our
results indicate that the local intracerebral microinfusion of
antiangiogenic compounds is an effective way to overcome
the logistical problems of inhibiting glioma-induced angio-
genesis.
INTRODUCTION
For the past several decades, the standard therapy for
malignant gliomas consisting of surgical removal and postop-
erative radiation has undergone extensive improvements from a
technical viewpoint. However, the clinical outcome of these
patients still remains poor, with an average survival after diag-
nosis of only 12–18 months (1). Tumor-induced angiogenesis is
a promising therapeutic target and its inhibition has shown
efficacy in a variety of experimental tumor models (2–5). The
increased metabolic requirements during the malignant progres-
sion of a tumor and the dependency on paracrine factors
provided by angiogenic active endothelial cells are the major
rationales for the therapeutic concept of inhibiting the tumor-
induced neovascularization (6, 7). Because angiogenesis de-
pends on the local net result between positive and negative
regulators it has been suggested that the prolonged, daily deliv-
ery of antiangiogenic therapy is the most effective way to obtain
long-term suppression of tumor angiogenesis (6, 8).
An important advantage of a direct antiangiogenic ap-
proach is that it targets primarily the angiogenic active endo-
thelial cells and not the tumor cell compartment. Therefore, the
blood–brain barrier does not need to be overcome, and the
logical delivery method of antiangiogenic compounds seems to
be the systemic delivery, for example, by intravascular admin-
istration. Daily systemic administration of antiangiogenic com-
pounds requires large quantities of purified protein and a high
patient compliance. Furthermore, it is well known that tumors
display a highly impaired and heterogeneous blood flow that
decreases toward the center of the tumor, inevitably leading to
hypoxia and tumor necrosis (9). Thus, even under optimized
conditions, it is questionable whether sufficient concentrations
of therapeutic compounds within and throughout the tumor can
be achieved (10).
The direct infusion of therapeutic compounds into brain
tumors can overcome some of the obstacles of drug delivery.
First clinical trials using intratumoral infusions of cytotoxic
compounds have recently demonstrated encouraging therapeutic
effects with an acceptable local safety and minimized systemic
toxicity (11, 12). Although it circumvents the blood–brain bar-
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rier, local intracerebral (i.c.) microinfusions were effectively
used using various conventional chemotherapeutic drugs in ex-
perimental brain tumor models (13, 14). The drug containing
fluids distribute by bulk flow (convection-enhanced) homoge-
neously through the interstitial space, and, depending on the
infusion pressure, higher local drug concentrations and more
distant areas of the brain can be reached (15). Because 90% of
the malignant gliomas recur within 2–3 cm of the resection site
(16), local infusions of therapeutic compounds may be able to
delay or prevent tumor recurrence.
In this study, we demonstrate that the local i.c. microinfu-
sion of the well-known antiangiogenic compound endostatin is
safe and more effective in the treatment of established ortho-
topic human glioblastoma xenografts than is the daily systemic
delivery. These results suggest a potential role for the direct i.c.
infusion of antiangiogenic compounds for the clinical manage-
ment of malignant glioma.
MATERIALS AND METHODS
Cell Culture. The human glioblastoma cell line U87
(American Type Culture Collection, Manassas, VA) was cul-
tured in MEM (Life Technologies, Inc., Grand Island, NY)
supplemented with 2 mM L-glutamine, 2 mM sodium pyruvate,
100 units/ml penicillin, 100 g/ml streptomycin, 0.25 g/ml
fungizone, and 10% fetal bovine serum (Life Technologies,
Inc.). Cells were maintained in T-75 tissue culture flasks in 5%
CO2/95% air at 37°C in a humidified incubator and were rou-
tinely passaged at confluency. For the intracranial implantation
experiments, U87 cells were dispersed with a 0.05% solution of
trypsin/EDTA (Life Technologies, Inc.), were washed with
PBS, and were adjusted to a final concentration of 5  104
cells/10 l in PBS.
Animal Studies. All of the animal work was carried out
in the animal facility at Brigham and Women’s Hospital in
accordance with federal, local, and institutional guidelines.
Tumor Models and Treatment Schemes. Orthotopic
human glioblastoma xenografts were established in 4–6-week-
old male Swiss nude mice (Taconic, Germantown, NY). Mice
were anesthetized (100 mg/kg ketamine and 5 mg/kg xylazine)
and received a stereotactically guided injection of 5  104
human U87 glioma cells into the left forebrain (2 mm lateral and
1 mm anterior to bregma, at a 3-mm depth from the skull
surface). Eight days after tumor cell injection, groups of 5–10
mice were randomized. For the systemic treatment groups, mice
received a total daily dosage of 20 mg/kg of murine (derived
from Escherichia coli) or human recombinant endostatin (solu-
ble human protein derived from Pichia pastoris; provided by Dr.
Judah Folkman, Children’s Hospital, Boston, MA and En-
treMed, Rockville, MD) as i.p. injections every 12 h. The
control animals of the systemic treatment groups were given i.p.
injections with PBS only. For the local delivery scheme, Alzet
osmotic minipumps, designed to deliver 0.25 l/h for 4 weeks,
were used (Durect Corporation, Cupertino, CA). The pumps
were filled with 2 mg/kg/day murine endostatin, or PBS for the
control animals, and connected to a brain infusion cannula via a
catheter tube according to the manufacturer’s instructions (Brain
Infusion Kit, Durect). To establish a constant flow before im-
plantation, the filled pumps were incubated overnight in sterile
PBS at 37°C. Previous experiments have demonstrated the sta-
bility and biological activity of endostatin contained in a pump
over a prolonged time period (17). Eight days after the injection
of U87 glioma cells, the pump reservoirs were placed s.c. in the
left flank of the anesthetized mice. The brain infusion cannula
was tunneled s.c. and fixed on the skull with surgical glue
slightly posterior to the initial tumor cell injection site resulting
in an intraparenchymal localization of the cannula tip (2–2.5
mm deep). Closure of the incisions was performed by suturing.
Each experiment was performed in duplicate.
Glioma Surgical Resection Model. To mimic the clin-
ical scenario more closely, we also used the recently developed
glioma surgical resection model as described previously (18).
Briefly, 20 days after U87 cell injection, established human
gliomas were surgically removed using a microsurgical tech-
nique. At that time, some degree of tumor cell invasion had
occurred resulting in the formation of small tumor satellites
distant from the main tumor mass. Microsurgical removal was
pursued until clear resection margins were visible. After achiev-
ing hemostasis, the incision was closed by suturing. One day
after surgery, mice were randomly divided, and systemic treat-
ment with 20 mg/kg/day of murine endostatin started. All of the
groups were sacrificed by CO2 inhalation 21 days after treat-
ment was initiated or when signs of neurological dysfunction
were apparent. Brains were removed, embedded in OCT, and
stored at80°C until further processed for histological analysis.
Survival Study. The effects of a local microinfusion of
endostatin on the survival of nude mice with established human
glioblastoma xenografts were assessed by implantation of os-
motic minipumps 8 days after tumor-cell injections, as described
above. Pumps were filled either with PBS for the control ani-
mals or with human endostatin at 2 mg/kg/day and 12 mg/kg/
day in a PBS solution. Animals were sacrificed at the onset of
neurological signs.
Magnetic Resonance Imaging (MRI). Five mice from
each of the groups with established tumors receiving the sys-
temic (20 mg/kg/day i.p. murine endostatin or PBS) and the
local delivery (2 mg/kg/day i.c. murine endostatin or PBS)
treatment were randomly chosen at the end of the experiments
(day 21 after treatment start). Tumor growth was evaluated on a
Bruker 8.5 T DRX vertical bore micro-imaging system (Bruker
Instruments, Billerica, MA). Gadopentetate dimeglumine (Gd-
DTPA; Berlex Laboratories, Wayne, New Jersey) was admin-
istered i.p. (0.8 ml/kg body weight) and the mice were anesthe-
tized with 1% isoflurane (Abbott Laboratory, North Chicago,
IL) in oxygen. Brain infusion cannulas were carefully removed
before positioning using a rigid bite-bar. Respiratory rates were
monitored using a Bruker Physiogard vital sign monitor. Gd-
enhanced T1-weighted spin-echo images were obtained for tu-
mor segmentation and three-dimensional rendering to calculate
tumor volumes [three-dimensional analysis software 3D Slicer
(19)]. T1-weighted post-Gd images were obtained 15 min after
contrast injection using TR 1000 ms, TE 8.8ms with a slice
thickness of 0.75 mm, matrix size of 128  128 and a 2.56 
2.56 cm2 field of view. Immediately after imaging, the animals
were sacrificed by CO2 inhalation, and the brains were removed
for histological analysis.
Immunohistochemistry. Frozen brains embedded in
OCT were cut in serial 10-m sections and were stained with
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H&E for histological evaluation. Tumor volumes were calcu-
lated by the ellipsoid formula. Immunohistochemistry was car-
ried out using standard techniques with the Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA). Primary anti-
bodies included anti-CD31 (1:100; BD Biosciences PharMin-
gen) for blood vessels, anti-Ki67 nuclear antigen (1:100,
DAKO, Carpinteria, CA) for proliferating cells, and anti-
cleaved Caspase 3 (1:100; Cell Signaling Technology, Beverly,
MA) for the detection of apoptosis. Sections were counter-
stained with hematoxylin, and negative control slides were
obtained by omitting the primary antibody. The proliferation
and apoptosis index were quantified by counting the number of
positively stained cells of 100 nuclei in five randomly chosen
high-power fields. The microvessel density was assessed as
described by Leon et al. (20) For the identification of hemosid-
erin deposits as a sign for micro-hemorrhages, we used the
Prussion-Blue reaction with a neutral red counterstain.
Statistics. All of the values were calculated as mean 
SE or were expressed as percentage of control SE. Significant
differences between tumor volume, microvessel density, prolif-
eration, and apoptosis index were determined using the Mann-
Whitney rank-sum test (MW test) or the unpaired t test. Kaplan-
Meier survival curves were statistically analyzed using Cox
regression analysis.
RESULTS
Systemic versus Local i.c. Treatment of Human Glio-
mas with Endostatin. Local i.c. microinfusions were estab-
lished by implantation of osmotic-minipumps in the near vicin-
ity of the tumor site 8 days after glioma cell injection. The direct
intraparenchymal release of a daily total dose of 2 mg/kg of
murine endostatin for 21 days resulted in significant tumor
growth inhibition (73.6%, P  0.05). A 10-fold higher systemic
treatment (2/day: 10 mg/kg  total daily dosage of 20 mg/kg
i.p.) with murine endostatin for 21 days had no significant effect
on the inhibition of tumor growth of established orthotopic
human glioblastoma xenografts (Fig. 1A). In contrast, histolog-
ical analysis revealed that the intratumoral blood vessel density,
as assessed by CD31 immunoreactivity, was significantly re-
Fig. 1 The local intracerebral (i.c.) microinfusion of murine endostatin (2mg/kg/day i.c.) via osmotic pumps is more effective than systemic i.p.
administration of 20 mg/kg/day on established U87 human glioblastoma xenografts in nude mice. A, direct i.c. delivery of 10-fold less murine
endostatin (2 mg/kg/day) inhibited the tumor volume by 74% (, P 0.05) as assessed by histological volume measurements. B, histological analysis
after 21 days of treatment indicated a significant reduction of vessel density (CD31) for the systemic treatment by 26.9% (, P  0.005) and for the
local delivery by 33.5% (, P  0.005). C, apoptotic cells were identified by immunoreactivity for cleaved Caspase 3. Only the local microinfusion
of endostatin induced a highly significant 3-fold increase of the apoptotic index (, P  0.002). D, the proliferative index based on Ki67
immunoreactivity remained unchanged in both treatment schemes.
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duced in both treatment schemes. The local microinfusion of
endostatin reduced the blood vessel density by 33.5% (P 
0.005), and the systemic treatment reduced the blood vessel
density by 26.9% (P  0.005) as compared with the respective
control groups (Fig. 1B). However, only the local microinfusion
of 2 mg/kg/day endostatin induced a 3-fold increased apoptosis
index (P 0.002; Fig. 1C). No difference in the apoptosis index
of the systemic treatment group was observed, and the prolif-
erative activity of the tumors in all of the treatment groups
remained unchanged (Fig. 1D). Histological screenings on the
brain sections did not reveal any signs of intratumoral hemo-
siderin deposits, indicating that the antiangiogenic treatment did
not induce any i.c. bleeding. Only rarely were minor hemosid-
erin deposits identified at a distance from the tumor site with no
predisposition for control or treated animals or the cannula site
of the pump. All of the pump reservoirs displayed a decreased
volume at the end of the experiments, indicating that endostatin
was delivered as expected.
In the glioma resection model, the cytoreduction by the
surgical removal of the main tumor mass followed by the
systemic treatment scheme with 20 mg/kg/day of endostatin i.p.
did not result in a significant reduction of tumor recurrence
when compared with the respective control group (control
82.18  38 mm3 versus treated 45.66  13 mm3). In both
groups, the invading cells that remained in the distant paren-
chyma after surgery inevitably regrew to form new tumor
masses. Histological analysis revealed a significant inhibition of
the intratumoral blood vessel density by 34% (P  0.05) and an
increase of the apoptotic index (control 8.5  2% versus treated
16.14  4.62%; P  0.05). The proliferative activity in tumors
of both groups remained unchanged. None of the animals from
any of the groups showed any signs of side effects due to the
treatment.
Assessment of Treatment Effects by MRI. The evalu-
ation of new therapeutic approaches can benefit from noninva-
sive MRI methods to quantify in vivo antitumor activity in
experimental animal models. Randomly chosen subsets of ani-
mals (n  5 each) from the original groups having received 21
days of systemic or local i.c. treatment of endostatin, or vehicle
only (PBS) were imaged using an 8.5T MRI scanner, and
Fig. 2 Examples of Gd-enhanced T1-weighted MR images with human glioblastoma xenografts and corresponding histological sections. A, the
T1-weighted image of a large control tumor in the left hemisphere having received a local microinfusion of PBS for 21 days displayed a highly
heterogeneous contrast enhancement with some spared areas in the center (arrows). B and C, giving the impression that these correspond to the large
blood vessels seen in the center of the tumor (arrows) on the corresponding blood vessel stained (CD31) section. The blood vessel stain demonstrates
the highly heterogeneous vascularization of the control tumor. D, in contrast, the T1-weighted image of a tumor treated with a local microinfusion
of endostatin (2 mg/kg/day) for 21 days shows a small contrast-enhancing mass in the left hemisphere (arrows). E and F, the corresponding blood
vessel stain reveals a reduced and more regular formed vascularization of the treated glioblastoma xenograft. Scale bar, 500 m.
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Gd-enhanced T1-weighted images were acquired. Orthotopic
human glioblastoma xenografts were seen as very heterogene-
ous high-signal-intensity areas in the left hemisphere correlating
with the corresponding histological sections (Fig. 2, A–C and 2,
D–F). Three-dimensional reconstructions of Gd-enhanced T1-
weighted images demonstrated the differences in tumor size
between the control and treated mice having received local i.c.
microinfusions (Fig. 3, A and B). The local microinfusion of
endostatin resulted in an 85.3% reduction of tumor volume
based on the quantification of the MR images compared with the
control group. Systemic treatment showed no significant differ-
ence in tumor volume (Fig. 3C), as has also been demonstrated
by histological analysis.
Effects of the Local Microinfusion of Endostatin on the
Survival of Human Intracranial Glioma-Bearing Nude
Mice. To assess whether the local i.c. microinfusion of en-
dostatin would result in an increased survival time of nude mice
with established orthotopic human glioblastoma xenografts,
minipumps were implanted in the near vicinity of the tumor 8
days after tumor cell injection. The pump reservoirs were filled
with either PBS for the control group or human endostatin at a
total daily dosage of 2 mg/kg or 12 mg/kg. Similar to the
findings using murine endostatin, the systemic treatment with
human endostatin at 20 mg/kg/day was not effective in the
treatment of established glioma xenografts (data not shown). We
found no significant changes between the control and treated
animals in blood vessel density, proliferation, or apoptosis in-
dex. In contrast, the i.c. microinfusion of 2 mg/kg/day human
endostatin by osmotic minipumps significantly increased the
survival time compared with the control group (P  0.006; Fig.
4). Increasing the total daily dosage to 12 mg/kg endostatin
prolonged the survival time (P  0.003; Fig. 4). The median
survival time was increased by eight days compared with the
controls. At day 36, the pump reservoirs were empty, and the
Fig. 3 Treatment effects as as-
sessed by magnetic resonance
imaging. Two representative
three-dimensional reconstruc-
tions of Gd-enhanced T1-
weighted images, obtained
from animals 21 days after
treatment start with the local in-
tracerebral (i.c.) microinfusion
of PBS (A) or endostatin (B) at
2 mg/kg/day. The local i.c. mi-
croinfusion of 2 mg/kg/day en-
dostatin clearly induced a re-
duction of tumor volume. On
the basis of the quantification
of the Gd-enhanced T1 MR im-
ages in the randomly selected
subset of animals (n 5/group)
systemic endostatin treatment
with 20 mg/kg/day endostatin
did not result in a significant
reduction of tumor volume (C,
left panel). In contrast, local i.c.
delivery of a 10-fold lower
amount of endostatin resulted
in an 85.3% reduction of tumor
volume (C, right panel).
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remaining mice of the 2 mg/kg/day endostatin group were
sacrificed. Reservoirs from animals of the 12-mg/kg/day-
endostatin group were not changed. As expected from previous
experiments, withdrawal of antiangiogenic therapy leads to pro-
gression of tumor growth (21), and the experiment was termi-
nated at day 48 after tumor cell injection.
DISCUSSION
Endostatin, a Mr 20,000 cleavage product of collagen
XVIII, is a potent inhibitor of tumor-angiogenesis (4, 5, 17) by
negatively affecting a variety of endothelial cell functions like
proliferation, migration, survival, and proteinase activity (22).
Achieving and maintaining therapeutic effective levels of en-
dostatin is hindered by the short half-life of the protein (17). We
have previously demonstrated that the continuous release of
endostatin from locally implanted alginate encapsulated cells
can inhibit the growth of s.c. human glioma xenografts by 72%
inhibition (5). However, angiogenesis is thought to be regulated
differently depending on the tissue environment of the tumor
(23). Therefore, we conducted the present study in an i.c.,
orthotopic model and started the treatment schemes after the
injected glioma cells had grown to a well-established vascular-
ized tumor mass.
We demonstrated that local i.c. administration of endosta-
tin at a total daily dose of 2 mg/kg via osmotic minipumps
inhibited the growth of established intracranial gliomas by
73.6% and was associated with a decrease in blood vessel
density and a significant increase in apoptosis. In contrast, the
systemic administration of a 10-fold higher daily dosage deliv-
ered at 10 mg/kg every 12 h in animals bearing established
gliomas or after surgical removal of the main tumor mass did
not cause a significant therapeutic effect, although the tumors
were significantly less vascularized when compared with the
respective control groups. This indicates that systemically ad-
ministered endostatin at a dose of 20 mg/kg/day actively inhib-
ited the tumor-induced angiogenesis, but was not sufficient to
suppress the tumor vascularization below the metabolic de-
mands of the tumor and, therefore, eliciting a reduction of
glioma growth. Noteworthy, in this context, the efficiency of an
antiangiogenic therapy is not directly reflected by changes of the
intratumoral blood vessel density and is, rather, an indicator of
antiangiogenic activity of a compound (24). Although the same
dosage has been effective in a variety of other cancer types (4,
17), our results are in line with Sorensen et al. (25) who also
demonstrated only a modest effect of systemically administered
endostatin at 20 mg/kg/day when tested in an intracranial rat
gliosarcoma model.
One possibility for the failure of systemically delivered
endostatin may be the impaired blood flow in a growing tumor
mass reducing the availability of systemically administered en-
dostatin in some angiogenic active areas. Especially newly
formed tumor vessels are very often not functional and display
a diminished and fluctuating blood flow or do not participate in
the microcirculation at all (10, 26). We were recently able to
demonstrate by perfusion MRI that the orthotopic U87 glioblas-
toma xenograft model used in this study follows the classical
view of a heterogeneous and decreasing blood flow toward the
center of a tumor (27).
The higher therapeutic efficacy of local i.c. delivery can be
due to numerous factors: (a) local delivery directly to the tumor
site circumvents the presence of the blood–brain barrier, which
can impede entry of the drug into the brain; (b) it reduces the
likelihood of degradation of the protein by endogenous pro-
teases before it reaches the target 3. Higher concentrations and
a more homogeneous distribution are achieved at the tumor site.
Conflicting results exist about how endostatin affects endothe-
Fig. 4 The continuous intrace-
rebral microinfusion of human
endostatin (Endo) by osmotic
minipumps increased the sur-
vival time of nude mice bearing
established U87 human glio-
blastoma xenografts (P 
0.006). Twelve mg/kg/day of
human endostatin (Endo 12 mg/
kg) further increased the sur-
vival time (P  0.003).
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lial cell physiology, and the structure of a potential primary
endostatin receptor is still not known (22). It cannot be excluded
that the therapeutic effects of locally applied endostatin are
enhanced because of the additional exposure of the angiogenic
active endothelial cells from the blood vessel abluminal side,
therefore, directly disturbing essential cell-matrix interactions
(22, 28). Furthermore, recent studies raise a controversy that
endostatin may have direct effects on tumor cells (28, 29).
However, these effects have been cell line-dependent and need
to be further evaluated.
This study confirms previous work in the treatment of
experimental brain tumors that local delivery can decrease the
quantity of drug needed (30). In our study, endostatin induced a
reduction of tumor angiogenesis but did not result in increased
glioma invasiveness, as has been seen by others when inhibiting
vascular endothelial growth factor-mediated angiogenesis in
experimental gliomas (5, 31). In addition, no signs of intracra-
nial bleeding due to the presence of the pumps or antiangiogenic
treatment were observed, which lends further support for direct
clinical application. Furthermore, we successfully implemented
the use of MRI for assessing the treatment effects of endostatin
in our animal model. Using this noninvasive technique allows us
to monitor dynamic changes of tumor growth in response to
treatment over a period of time. Delivery and scheduling of
angiogenesis inhibitors in combination with other therapeutic
approaches are of particular importance for the successful clin-
ical integration of antiangiogenic therapies (8). In this respect,
MRI in experimental animal models will provide an important
tool for the development of new treatment schemes.
In summary, our data demonstrate that the local microin-
fusion of endostatin is able to inhibit tumor growth and increase
survival of animals with orthotopic malignant gliomas. Local
continuous i.c. delivery is more effective than daily systemic
delivery. I.c. infusions for malignant gliomas are in clinical
trials, appear safe and feasible, and could immediately be used
for the delivery of endostatin or other angiogenesis inhibitors in
patients with malignant tumors.
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